Novo says its next-gen obesity drug tops Lilly rival in late-stage study
21/09/2026 11:44
Novo says its next-gen obesity drug tops Lilly rival in late-stage study Sept 21 (Reuters) - Novo Nordisk NOVOb.CO said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly's LLY.N drug.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals